These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 2542913)
21. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Zegura B; Guzic-Salobir B; Sebestjen M; Keber I Menopause; 2006; 13(4):643-50. PubMed ID: 16837886 [TBL] [Abstract][Full Text] [Related]
22. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding. Yildirim G; Tugrul S; Uslu H; Pekin O; Eren S Arch Gynecol Obstet; 2006 Feb; 273(5):268-73. PubMed ID: 16315025 [TBL] [Abstract][Full Text] [Related]
23. Endocrine approach in the management of dysfunctional uterine bleeding. Garcia CR Clin Obstet Gynecol; 1970 Jun; 13(2):460-73. PubMed ID: 4322145 [No Abstract] [Full Text] [Related]
24. Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. Erenus M; Karakoç B; Gürler A Climacteric; 2001 Sep; 4(3):228-34. PubMed ID: 11588947 [TBL] [Abstract][Full Text] [Related]
25. Three-year study of estrogen alone versus combined with progestin in postmenopausal women with or without hypercholesterolemia. Sanada M; Nakagawa H; Kodama I; Sakasita T; Ohama K Metabolism; 2000 Jun; 49(6):784-9. PubMed ID: 10877207 [TBL] [Abstract][Full Text] [Related]
26. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study. Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J; Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189 [TBL] [Abstract][Full Text] [Related]
27. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy. Kim CJ; Min YK; Ryu WS; Kwak JW; Ryoo UH Arch Intern Med; 1996 Aug 12-26; 156(15):1693-700. PubMed ID: 8694668 [TBL] [Abstract][Full Text] [Related]
28. Mechanisms of uterine bleeding in postmenopausal patients receiving estrogen alone or with a progestin. Flowers CE; Wilborn WH; Hyde BM Obstet Gynecol; 1983 Feb; 61(2):135-43. PubMed ID: 6296742 [TBL] [Abstract][Full Text] [Related]
30. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. Mueck AO; Seeger H; Wallwiener D Climacteric; 2003 Sep; 6(3):221-7. PubMed ID: 14567770 [TBL] [Abstract][Full Text] [Related]
31. Effects of oral and transdermal hormone replacement therapy on internal carotid artery pulsatility indices in postmenopausal women. A prospective, randomized, comparative study. Sendağ F; Terek MC; Karadadaş N; Bilgin O J Reprod Med; 2001 Nov; 46(11):962-8. PubMed ID: 11762152 [TBL] [Abstract][Full Text] [Related]
32. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms. Cieraad D; Conradt C; Jesinger D; Bakowski M Arch Gynecol Obstet; 2006 May; 274(2):74-80. PubMed ID: 16491367 [TBL] [Abstract][Full Text] [Related]
33. Postmenopausal hormone therapy offers no protection against heart attacks. American Medical Association Ginecol Obstet Mex; 2002 Aug; 70():404-5. PubMed ID: 12448045 [No Abstract] [Full Text] [Related]
34. [Effect of combined conjugated estrogen-medrogestone replacement therapy on lipid profiles, climacteric symptoms and the endometrium]. Belaisch J; Nappi C; Affinito P; De Gezelle H; Botelho M; Oliveira HM; Martinez-Oliveira J; Gonzaga F J Gynecol Obstet Biol Reprod (Paris); 2000 Feb; 29(1):29-40. PubMed ID: 10675831 [TBL] [Abstract][Full Text] [Related]
35. New delivery systems for hormonal contraception. Odlind V Acta Obstet Gynecol Scand Suppl; 1986; 134():15-20. PubMed ID: 2949479 [No Abstract] [Full Text] [Related]
36. So far, victories are few as breast cancer patients sue Wyeth over hormone therapy. Twombly R J Natl Cancer Inst; 2007 Dec; 99(24):1828-9, 1835. PubMed ID: 18073368 [No Abstract] [Full Text] [Related]
37. [Transdermal estrogenic therapy in menopause]. Nencioni T; Polvani F; Penotti M; Porcaro E; Barbieri Carones M Minerva Endocrinol; 1989; 14(1):49-52. PubMed ID: 2543896 [TBL] [Abstract][Full Text] [Related]
38. Is expression of rat breast matrix components influenced by estrogen, progestins and tibolone? Cunha EP; Pompei LM; Theodoro TR; Steiner ML; Silva VF; Silveira ER; Mader AM; Pinhal MA; Fernandes CE Climacteric; 2015; 18(4):523-7. PubMed ID: 25603456 [TBL] [Abstract][Full Text] [Related]
39. [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol]. Milewicz T; Kostecka A; Rogatko I; Sztefko K; Kwiatkowska-Panek E; Radowick S; Krzysiek J Przegl Lek; 2007; 64(2):65-9. PubMed ID: 17892034 [TBL] [Abstract][Full Text] [Related]
40. Types of estrogen and delivery systems. Whitehead MI Postgrad Med; 1989 Apr; Spec No():78-83; discussion 89-90. PubMed ID: 2542912 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]